GlassScriptPhysician profile
Sandrivette V Johnson
NPI 1740201458
$572,549.94
in general payments reported to CMS, 2019-2025
37 companies · $107K in 2025
The $107K reported for 2025 was more than what 99% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $41K · 2022: $110K · 2023: $140K · 2024: $174K · 2025: $107K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $255K · Consulting Fee: $86K · Travel and Lodging: $53K · Food and Beverage: $24K · Honoraria: $2,948 · Education: $259 · Gift: $117.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $255,204.50 |
| Consulting Fee | $85,889.50 |
| Travel and Lodging | $53,382.94 |
| Food and Beverage | $23,998.73 |
| Honoraria | $2,948.11 |
| Education | $259.36 |
| Gift | $116.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $146,202.40 | 2021-2025 | |
| Janssen Biotech, INC. | $91,423.83 | 2021-2025 | Tremfya |
| Genzyme Corporation | $45,754.89 | 2021-2025 | |
| Lilly USA, LLC | $39,709.96 | 2021-2025 | Ebglyss, Taltz, Olumiant |
| Arcutis Biotherapeutics, INC. | $39,638.72 | 2023-2025 | Zoryve |
| E.R. Squibb & Sons, L.L.C. | $30,623.77 | 2022-2025 | Sotyktu |
| Ucb, INC. | $28,275.00 | 2021-2025 | Bimzelx, Cimzia |
| Leo Pharma INC. | $25,759.44 | 2021-2025 | Adbry, Anzupgo |
| Regeneron Healthcare Solutions, INC. | $22,355.87 | 2021-2025 | Dupixent |
| Janssen Scientific Affairs, LLC | $20,179.77 | 2021-2023 | Tremfya |
| Amgen INC. | $18,660.96 | 2021-2025 | Otezla, Otezla, Enbrel |
| Dermavant Sciences, INC. | $18,023.46 | 2022-2024 | Vtama |
| Galderma Laboratories, L.P. | $12,045.12 | 2021-2025 | Nemluvio, Aklief |
| Incyte Corporation | $8,453.67 | 2021-2025 | Opzelura |
| Eli Lilly and Company | $7,704.89 | 2024-2025 | Ebglyss, Taltz, Olumiant |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandrivette Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.